Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) will be announcing its earnings results before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of ($2.12) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.
Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) last posted its quarterly earnings data on Thursday, February 22nd. The company reported ($0.70) earnings per share for the quarter, meeting the consensus estimate of ($0.70). The business had revenue of $24.23 million for the quarter, compared to analysts’ expectations of $25.38 million. Rhythm Pharmaceuticals had a negative return on equity of 96.02% and a negative net margin of 238.50%. The business’s revenue was up 175.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.75) EPS. On average, analysts expect Rhythm Pharmaceuticals to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Rhythm Pharmaceuticals Stock Performance
Rhythm Pharmaceuticals stock traded up $1.25 during trading hours on Tuesday, hitting $40.07. 140,490 shares of the stock traded hands, compared to its average volume of 611,404. The firm’s 50-day moving average price is $41.39 and its two-hundred day moving average price is $39.08. Rhythm Pharmaceuticals has a one year low of $15.50 and a one year high of $52.57.
Analyst Upgrades and Downgrades
Check Out Our Latest Research Report on Rhythm Pharmaceuticals
Insider Activity at Rhythm Pharmaceuticals
In other Rhythm Pharmaceuticals news, insider Joseph Shulman sold 71,774 shares of the business’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $50.38, for a total transaction of $3,615,974.12. Following the completion of the sale, the insider now directly owns 2,686 shares in the company, valued at approximately $135,320.68. The sale was disclosed in a document filed with the SEC, which is available through this link. In other Rhythm Pharmaceuticals news, insider Joseph Shulman sold 71,774 shares of the business’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $50.38, for a total transaction of $3,615,974.12. Following the completion of the sale, the insider now directly owns 2,686 shares in the company, valued at approximately $135,320.68. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Yann Mazabraud sold 1,594 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $51.38, for a total transaction of $81,899.72. Following the sale, the executive vice president now owns 7,702 shares of the company’s stock, valued at $395,728.76. The disclosure for this sale can be found here. In the last three months, insiders have sold 172,069 shares of company stock valued at $7,626,355. 4.70% of the stock is owned by corporate insiders.
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.
Further Reading
- Five stocks we like better than Rhythm Pharmaceuticals
- 10 Best Airline Stocks to Buy
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- Consumer Staples Stocks, Explained
- Hilton Demonstrates Asset Light is Right for Investors
- How to Most Effectively Use the MarketBeat Earnings Screener
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.